- Home
- PHVS
PHVS
Pharvaris N.V.
as 07-26-2024 4:00pm EST
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases. The company's activities are considered to be one segment which comprises the discovery, development and commercialization of oral bradykinin-B2-receptor antagonists .
| Founded: | 2015 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 902.5M | IPO Year: | 2021 |
| Target Price: | $32.80 | AVG Volume (30 days): | 46.9K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.00 - $33.00 | Next Earning Date: | 08-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Pharvaris N.V. News
PHVS Breaking Stock News: Dive into PHVS Ticker-Specific Updates for Smart Investing
Investor's Business Daily
10 days ago
Three Surprising Names That Could Be On Biogen's Buyout Shortlist
GlobeNewswire
2 months ago
Pharvaris Announces Annual Meeting of Shareholders
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Reuters
2 months ago
Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
Insider Monkey
2 months ago
Best Date Night Fragrance in 2024
AFP
2 months ago
France's Macron calls snap legislative elections after EU poll blow
Compare PHVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHVS Pharvaris N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.